Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeHealthUVA Research Finds Antidepressant Fluvoxamine May Prevent Severe COVID-19

UVA Research Finds Antidepressant Fluvoxamine May Prevent Severe COVID-19

Pixabay-geralt

The University of Virginia, School of Medicine conducted a small trial of treating COVID-19 patients with fluvoxamine, an antidepressant. The clinical trial included 80 adult participants who were given the drug, while 72 were given a placebo. None of the 80 outpatients developed severe symptoms, nor were they hospitalized, unlike some who were given the placebo.

“The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function, “ said Eric J. Lenze, MD, of the Washington University School of Medicine. “Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our studies suggest fluvoxamine may help fill that niche.”

The researchers confirmed that the trial had a lot of limitations. It was a small trial. About a fifth of the participants stopped answering surveys during the 15-day duration of the trial. They are hopeful that a larger trial will show better results and it could become a perfect treatment for newly diagnosed COVID-19 patients.

Gaultier said, “Fluvoxamine is not an experimental drug, it is cheap and safe and could be used as a first line of defense to unburden the hospitals that are overwhelmed by the COVID health crisis.”

Source   wtop

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more